Bucolome

Bucolome
Clinical data
Other names	Bucolome, Paramidine
AHFS/Drugs.com	International Drug Names
ATC code	none;
Identifiers
	IUPAC name 5-butyl-1-cyclohexyl-1,3-diazinane-2,4,6-trione;
CAS Number	841-73-6;
PubChem CID	2461;
ChemSpider	2367 ;
UNII	9T08RAL174;
ChEBI	CHEBI:31314 ;
ChEMBL	ChEMBL2106136;
CompTox Dashboard (EPA)	DTXSID4048854 ;
ECHA InfoCard	100.011.515
Chemical and physical data
Formula	C14H22N2O3
Molar mass	266.341 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CCCCC1C(=O)NC(=O)N(C1=O)C2CCCCC2;
	InChI InChI=1S/C14H22N2O3/c1-2-3-9-11-12(17)15-14(19)16(13(11)18)10-7-5-4-6-8-10/h10-11H,2-9H2,1H3,(H,15,17,19) ; Key:DVEQCIBLXRSYPH-UHFFFAOYSA-N ;
	(verify)

Bucolome (Paramidine) is a barbiturate derivative. Unlike most barbiturates it does not have any significant sedative or hypnotic effects, but instead acts as an analgesic and antiinflammatory. It also acts as a CYP2C9 inhibitor and reduces the metabolism of several commonly used drugs, which makes it useful for potentiating or extending the duration of action of those drugs, or reducing the production of unwanted metabolites.^[1]^[2]^[3]

References

^ Takamura N, Maruyama T, Chosa E, Kawai K, Tsutsumi Y, Uryu Y, et al. (April 2005). "Bucolome, a potent binding inhibitor for furosemide, alters the pharmacokinetics and diuretic effect of furosemide: potential for use of bucolome to restore diuretic response in nephrotic syndrome". Drug Metabolism and Disposition. 33 (4): 596–602. CiteSeerX 10.1.1.658.6194. doi:10.1124/dmd.104.002782. PMID 15640375. S2CID 1184330.
^ Osawa M, Hada N, Matsumoto K, Hasegawa T, Kobayashi D, Morimoto Y, et al. (April 2005). "Usefulness of coadministration of bucolome in warfarin therapy: pharmacokinetic and pharmacodynamic analysis using outpatient prescriptions". International Journal of Pharmaceutics. 293 (1–2): 43–9. doi:10.1016/j.ijpharm.2004.12.009. PMID 15778043.
^ Kobayashi M, Takagi M, Fukumoto K, Kato R, Tanaka K, Ueno K (2008). "The effect of bucolome, a CYP2C9 inhibitor, on the pharmacokinetics of losartan". Drug Metabolism and Pharmacokinetics. 23 (2): 115–9. doi:10.2133/dmpk.23.115. PMID 18445991.

This analgesic-related article is a stub. You can help Wikipedia by expanding it.

[1] Takamura N, Maruyama T, Chosa E, Kawai K, Tsutsumi Y, Uryu Y, et al. (April 2005). "Bucolome, a potent binding inhibitor for furosemide, alters the pharmacokinetics and diuretic effect of furosemide: potential for use of bucolome to restore diuretic response in nephrotic syndrome". Drug Metabolism and Disposition. 33 (4): 596–602. CiteSeerX 10.1.1.658.6194. doi:10.1124/dmd.104.002782. PMID 15640375. S2CID 1184330.

[2] Osawa M, Hada N, Matsumoto K, Hasegawa T, Kobayashi D, Morimoto Y, et al. (April 2005). "Usefulness of coadministration of bucolome in warfarin therapy: pharmacokinetic and pharmacodynamic analysis using outpatient prescriptions". International Journal of Pharmaceutics. 293 (1–2): 43–9. doi:10.1016/j.ijpharm.2004.12.009. PMID 15778043.

[3] Kobayashi M, Takagi M, Fukumoto K, Kato R, Tanaka K, Ueno K (2008). "The effect of bucolome, a CYP2C9 inhibitor, on the pharmacokinetics of losartan". Drug Metabolism and Pharmacokinetics. 23 (2): 115–9. doi:10.2133/dmpk.23.115. PMID 18445991.

[1]

[2]

[3]